Coming Soon

The Native Antigen Company Limited

Registration Number 07386339

Trading name: The Native Antigen Company

The Native Antigen Company specializes in the development and production of native and recombinant antigens for use in research, diagnostics, and therapeutic applications. Their products are designed to assist in the study of infectious diseases and other medical conditions.

Company Overview

Company Name
The Native Antigen Company Limited
Registration Number
07386339
Founded
23 September 2010
Age
15 years
Industry Region
London
Registered Postcode
TW11 0LY

Online Profile

Special Flags

Public Funding Received

Public Funding for The Native Antigen Company Limited

2017-01-01
Development of a point-of-care, non-crossreacting Zika diagnostic test
Collaborative R&D
2016-03-01
Development of a novel, rapid and safe neutralising antibody diagnostic kit by The Native Antigen Company
GRD Proof of Concept
2014-08-01
A novel approach using VLP's to enhance the immunogenicity of peptides for generation of therapeutic Monoclonal antibodies.
GRD Proof of Concept
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-02-01
A novel virus-like particle based mammalian expression system targeted at vaccine development against envelope viruses.
Feasibility Studies
2013-01-01
The purification and production of toxins from emergent Clostridium difficile hypervirulent strains for use in Vaccine Research
GRD Proof of Concept
2012-03-01
The Native Antigen Company - Native antigens for rapid point of care diagnostics
GRD Proof of Concept

Get notified when we’re launching.

Want fast, powerful sales prospecting for UK companies? Signup below to find out when we're live.